Skip to content
Screener

Alamar Biosciences ALMR Total Liabilities

Total Liabilities at other companies

GPA
General Purpose Acquisition Corp.GPAC
$17.3M-28.7%
Veradermics logo
VeradermicsMANE
$6.72M—
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$1.01M—
Schering-Plough logo
Schering-PloughSGP
$8.27M—
Applied Materials logo
Applied MaterialsAMAT
$16.38B+11.6%
Dollar Tree logo
Dollar TreeDLTR
$10.32B-28.3%

Other financials

Income statement

See full
Revenue$26.0M+98.9%
Gross profit$14.5M+126%
Operating income-$12.3M-44.4%
Net income-$21.3M-178%
EPS (diluted)-$1.74-156%

Balance sheet

See full
Cash & equivalents$64.6M—
Total debt$30.6M—
Total equity-$178.1M—
Total assets$186.5M—

Cash flow

See full
Operating cash flow-$20.3M-55.7%
CapEx$600.0K+8.3%
Free cash flow-$20.9M-53.8%

Valuation

See full
Market cap$1.96B+37.6%
Enterprise value$1.93B—

Returns & leverage

See full
Debt / equity-0.2×—
Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026. Open the filing →

Filed
May 8, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-213424

FAQ

What is Alamar Biosciences's total liabilities?
Alamar Biosciences (ALMR) reported total liabilities of $129.53M in Q1 2026.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Alamar Biosciences's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude